 Home > Active Ingredient News > Drugs Articles > 2300 yuan / box!

2300 yuan / box!

 Last Update: 2022-04-28
 Source: Internet
 Author: User

Tags

glue meat products

100 tablet

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

In the tug of war with the new crown virus, the new crown oral drug is the last "cake" for the normalization of the epidemic, and the new crown small molecule oral drug represented by Pfizer's Paxlovid and Merck's molnupiravir has become the next outlet of the epidemic
.

It can be seen from the U.
S.
government’s new crown drug procurement data that since the new crown oral drug was launched, the number of antibody drugs purchased by the U.
S.
government has declined, and the new crown oral drug procurement trend has increased significantly
.

According to Pfizer's 2021 performance report data released on February 8, Pfizer's revenue in 2021 will be US$81.

A recap of events surrounding Paxlovid

In November 2021, Pfizer announced that it had reached an agreement with the United Nations-backed MPP (Medicines Patents Organization) to allow other generic drugmakers to manufacture its oral Covid-19 drug Paxlovid
.

In the generic drug licensing agreement signed with MPP, China is not included in the list of generic drugs that can be sold to the market

What is Paxlovid?

Paxlovid is a combination antiviral drug consisting of two tablets
.

One of the tablets is Nirmatrelvir (150mg), which is a 3CL protease (also called main protease, Mpro) inhibitor of the new coronavirus

What other new crown oral drugs?

In the last year, progress has been made in a number of different types of new crown treatment drugs, such as new crown neutralizing antibody therapy, small molecule new crown drugs,
etc.

The four blockbuster products that have received the most market attention are Pfizer (3CL protease inhibitor), Kintor Pharmaceutical (AR antagonist), Roche (RNA polymerase inhibitor), Merck (RNA polymerase inhibitor), the four major pharmaceutical companies.

In China, many domestic pharmaceutical companies have deployed a variety of oral anti-new crown drugs
.

According to the research report of Huachuang, the "Azvudine (oral)" of Real Bio is in the clinical phase III; the "VV16 (oral)" of Junshi Bio/Wangshan Wangshui/Chinese Academy of Sciences has started the clinical phase II/III Research; Oral 3CL inhibitors from companies such as Ascletis, Simcere, Zhongsheng, and Junshi are in the preclinical research stage and are expected to enter the clinic in the next 6 months

Image source: "Better than Pfizer! The first 3CL new crown specific drug to enter the clinic in China, or it may have been licensed! 》

Medicine Times will continue to pay close attention and report in a timely manner

Reference article:

One article to understand the new crown treatment drug nematevir / ritonavir tablets (Paxlovid)

100% cure rate? How "God" is this new crown oral drug?

New crown oral drug late-night news: 5 Chinese companies are allowed to imitate! Are these A-share companies going to be hi?

Better than Pfizer! The first 3CL new crown specific drug to enter the clinic in China, or it may have been licensed!

Pfizer revisits the invention of Paxlovid

Pfizer's MPP provokes another turmoil, but the capital market doesn't buy it

Pfizer Announces Initiation of Clinical Trial of mRNA Flu Vaccine

other information

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.